Factores clínicos y epidemiológicos asociados con nefritis lúpica en pacientes del noroccidente colombiano by Anaya, Juan Manuel et al.
293
LUPUS NEPHRITIS IN COLOMBIANSBiomédica 2003;23:293-300
Clinical and immunological factors associated with lupus
nephritis in patients from northwestern Colombia
Juan Manuel Anaya 1,2, Mauricio Uribe 3, Adriana Pérez 4, Juan F. Sánchez 1, Luis F. Pinto 5,
José F. Molina 5, María C. Londoño 1, Martha E. Cadavid 2, Gustavo Matute 6
1 Clínica Universitaria Bolivariana, Facultad de Medicina, Universidad Pontificia Bolivariana, Medellín, Colombia.
2 Corporación para Investigaciones Biológicas, Medellín, Colombia.
3 Centro de Terapia Renal Bolivariano, Clínica Universitaria Bolivariana, Medellín, Colombia.
4 The University of Texas at Houston, Brownsville, USA; Pontificia Universidad Javeriana, Bogotá, D.C.,
Colombia.
5 Hospital Pablo Tobón Uribe, Medellín, Colombia.
6 Laboratorio de Patología, Facultad de Medicina, Universidad Pontificia Bolivariana, Medellín, Colombia.
A cross-sectional and multicenter study was undertaken to analyze the clinical and
immunological characteristics at diagnosis associated with nephritis in northwestern
Colombian patients with systemic lupus erythematosus (SLE). Thirty nine patients with lupus
nephritis were included and were compared to 100 SLE patients without nephritis. A multivariate
analysis was performed. The patients who developed nephritis had a higher frequency of oral
ulcers (41% vs. 21%, OR=3.1, 95%CI: 1.3-7.5 p= 0.01) and malar erythema (77% vs. 45%,
OR=4.4, 95%CI: 1.8-10.8 p=0.001). Lupus nephritis was observed in 77% of cases during the
first year of the disease. The frequency of anti-DNA antibodies was higher in patients with
nephritis, however, differences were not statistically significant (83% vs 64%, OR=2.6, 95%CI:
1.03-6.41, p=0.06). The presence of other autoantibodies (anti-Ro, anti-La, anti-RNP, anti-Sm
and anticardiolipin) at diagnosis was similar in both groups. This autoantibody profile remained
unchanged throughout the evolution of the disease. Patients with lupus nephritis had a higher
prevalence of arterial hypertension (60% vs 10%, OR=13.7, 95%IC: 5-37, p=0.00001) and
hyperlipidemia (30% vs 7%, OR=8.1, 95%IC: 2.5-27, p=0.0006) at onset. Finally, patients with
lupus nephritis required more hospitalizations (>1) over the course of disease (89% vs 60%,
OR=7.8, 95%CI: 2.1–29, p=0.002). In conclusion, lupus nephritis appears early during the
course of SLE. Malar erythema, oral ulcers, hypertension and hyperlipidemia at onset of disease
are associated factors. Lupus nephritis is a major risk factor leading to repeated
hospitalizations. This study may help to assist in public health policies in our population in
order to improve patient outcomes while simultaneously reducing disease costs.
Key words: systemic lupus erythematosus, lupus nephritis, risk factors, autoantibodies,
hypertension, hyperlipidemia, Colombia.
Factores clínicos y epidemiológicos asociados con nefritis lúpica en pacientes del
noroccidente colombiano
Este estudio transversal y multicéntrico investigó las características clínicas e inmunológicas
asociadas con la nefritis lúpica en pacientes colombianos de Medellín. Se incluyeron treinta y
nueve pacientes con nefritis lúpica y se compararon sus características con las de 100 pacientes
con lupus eritematoso sistémico (LES) sin compromiso renal. Se realizó un análisis multivariado
para evaluar los factores asociados con la nefritis lúpica. Los pacientes que desarrollaron
nefritis presentaron, al inicio, más úlceras orales (41% vs. 21%, OR=3,1, IC95%: 1,3-7,5, p=0,01)
y eritema malar (77% vs. 45%, OR=4,4, IC95%: 1,8-10,8, p=0,001) que aquellos pacientes sin
nefropatía. La nefritis lúpica se observó en 77% de los casos durante el primer año de evolución
del LES. La frecuencia de anticuerpos anti-ADN fue mayor en los pacientes con nefritis; sin
embargo, las diferencias no fueron significativas (83% vs. 64%, OR=2,57, IC95%:1,03-6,41,
p=0,06). La presencia de otros anticuerpos (anti-Ro, anti-La, anti-RNP, anti-Sm y anticardiolipina)
en el momento del diagnóstico fue similar en ambos grupos. El perfil de los autoanticuerpos
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permaneció sin modificación significativa durante el curso del LES. Los pacientes con nefritis
lúpica presentaron una mayor prevalencia de hipertensión arterial (60% vs 10%, OR=13,7,
IC95%: 5-37, p=0,00001) y dislipidemia (30% vs 7%, OR=8,1, IC95%: 2,5-27, p=0,0006) al
inicio de la enfermedad que aquellos pacientes sin nefropatía. Los pacientes con nefritis lúpica
requirieron más hospitalizaciones (>1) durante el curso de la enfermedad (89% vs 60%, OR=7,8,
IC95%: 2,1-29, p=0,002). En conclusión, la nefritis lúpica se presenta tempranamente en el
LES. El eritema malar, las úlceras orales, la hipertensión arterial y la dislipidemia son factores
asociados. A su vez, la nefritis lúpica es un factor de riesgo de hospitalizaciones repetidas. Este
estudio puede ser útil en la toma de decisiones de políticas de salud para beneficio de los
pacientes y reducción de costos.
Palabras clave: lupus eritematoso sistémico, nefritis lúpica, factores de riesgo, autoanticuerpos,
hipertensión arterial, dislipidemia, Colombia.
Systemic lupus erythematosus (SLE) is an
autoimmune systemic disease characterized by
a loss of immunologic tolerance to a multitude of
self-antigens that may produce variable clinical
manifestations. The clinical course is characterized
by periods of remissions and acute or chronic
relapses. The reported prevalence of SLE is 40-
50 cases per 100,000 persons. Women in child-
bearing age, in particular African-Americans,
African-Caribbeans, Hispanic-Americans and
Asians, are at higher risk (1,2). The diverse
manifestations of SLE include the involvement of
skin, joints, nervous system, renal, and
hematological systems (3).
Lupus nephritis is one of the most serious
complications of SLE being the major predictor of
poor prognosis (2,3). The mortality is greater in
patients with lupus nephritis than in those without
renal damage (4). Among those patients with lupus
nephritis, near 70% develop renal insufficiency (2).
Diverse clinical manifestations have been
associated with lupus nephritis, the most
frequently being malar erythema, pericarditis and
arterial hypertension (5). The main laboratory
associated abnormalities reported are anemia and
low levels of serum complement. High titers of
antibodies anti-dsDNA have also been associated
with lupus nephritis activity (2). However, clinical
manifestations of SLE vary according to ethnicity
and geography (2). In this study we analyzed the
clinical and immunological characteristics of
patients with lupus nephritis from Medellin,
northwestern Colombia.
Patients and methods
Study population
This was a cross-sectional and multicenter study
done during the period of January to June 2002.
We included patients with lupus nephritis being
treated at rheumatology units in the Clínica
Universitaria Bolivariana, Corporación para
Investigaciones Biológicas (CIB), Hospital Pablo
Tobón Uribe, and Congregación Mariana, in
Medellín. All patients met at least four of the
classification criteria for SLE (6). In addition,
patients with SLE without nephritis were also
included. Patients without a complete medical
record or those who did not meet SLE diagnosis
criteria were excluded. From an ethical point of
view, the study complied with Resolution No.
008430, 1993, issued by the Ministry of Health of
the Republic of Colombia, and was classified as
minimal risk research. The CIB Ethics Committee
approved the study.
Clinical variables
Information on patient demographics and
cumulative clinical and laboratory manifestations
over the course of disease were obtained either
by verification during discussion with the patient
or by chart review, and were collected in a standard
data collection form created for that purpose.
Demographic, clinical and laboratory variables
were included in the collection form. A guide for
the data collection form was made to guarantee
its reproducibility (k>0.6). Each clinical and
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laboratory variable was registered as “present” or
“absent” for each specific patient at the moment
of diagnosis and then at any time during the course
of the disease.
The clinical and laboratory variables associated
with SLE, including each feature of the revised
ACR criteria (6), were evaluated and defined as
follows: 1) arthritis: non-erosive arthritis involving
two or more peripheral joints, characterized by
tenderness, swelling or effusion; 2) malar rash; 3)
photosensitivity; 4) alopecia; 5) discoid lupus; 6)
Raynaud’s phenomenon; 7) renal involvement: a
renal biopsy result demonstrating World Health
Organization (WHO) class II-V histopathology,
active urinary sediment or proteinuria >500 mg/
24 h. Nephrotic syndrome was defined as more
than 3.5 g/day of proteinuria, hypoalbuminemia
(less than 2.8 g/dl), hyperlipidemia and edema.
Lupus nephritis was defined as present or absent
according to the abnormalities of the previous
tests; 8) neurologic involvement, as evidenced by
seizures without any other definable cause, or
psychosis lacking any other definable cause, or
other conditions such as peripheral neuropathy,
stroke, transverse myelitis, chorea, or other central
nervous system lesions directly attributable to
SLE in the absence of other causes; 9) pleuritis:
pleural rub and/or effusion and/or typical pleuritic
pain; 10) pericarditis: documented by electro-
cardiogram, rub, or evidence of pericardial effusion;
11) autoimmune hemolytic anemia, with an
hematocrit count <35%, reticulocyte count >4%,
and positive Coombs test; 12) leukopenia, white
cells <4,000/mm3; 13) thrombocytopenia, platelets
<100,000/mm3; 14) arterial or venous thrombosis
diagnosed on clinical grounds and confirmed by
appropriate tests.
Comorbidity at the moment of the first evaluation
was also recorded, and included  the presence or
absence of arterial hypertension (blood pressure
levels >140/90); diabetes mellitus (fasting
glycemia >126 mg/dl in two occasions); coronary
disease (history of myocardial infarction, stable
or unstable angina), hyperlipidemia (LDL
cholesterol >130 mg/dl and triglycerides >150 mg/
dl); hypothyroidism (TSH >5 mU/L). The number
of hospitalizations during the course of the disease
was also registered.
Severity of disease
Disease severity and organ damage was
evaluated using the systemic lupus international
collaborating clinics (SLICC) damage index
(SDI) (7).
Autoantibodies
Antinuclear antibodies (ANA) were determined by
indirect immunofluorescence using HEp-2 cells as
substrate, and anti-dsDNA antibodies were
determined by indirect immunofluorescence with
Crithidia luciliae as substrate, and by ELISA.
Precipitating antibodies to extractable nuclear
antigens, including Sm, U1-RNP, Ro/SSA, La/
SSB, as well as anticardiolipin antibodies were
detected by ELISA using diverse commercial kits.
Statistical analysis
Descriptive statistical data was computed. For the
normal variables, mean and standard deviations
(SD) are reported, and for the non-normal variables,
medians and interquartile ranges (IQR) are
reported. The test for normality was that of
Kosmogrorov-Smirnov. The odd ratios (OR) are
reported with 95% confidence intervals. A level of
1% of significance was established. The Bonferroni
correction was done for multiple comparisons. A
multivariable analysis was done and adjusted by
age and time of duration of the disease through
the estimation of OR using non conditional logistic
regression. The analysis was performed using the
SPSS software (8).
Results
Thirty nine patients with lupus nephritis were
included in the study and were compared to 100
SLE patients without nephritis. The main clinical
characteristics present in patients are shown in
Table 1. The clinical manifestations at diagnosis
were similar in both groups (Table 1). However,
the multivariable analysis disclosed that patients
who developed nephritis had a higher frequency
of oral ulcers and malar erythema (Table 2). Lupus
nephritis was observed within the first year
following diagnosis in 30 (77%) cases. There were
6 (15%) cases of nephritis during the second year,
2 (5%) during the third year and one case (3%) at
the fifth year of the disease. Fifteen lupus nephritis
patients (38%) presented nephrotic syndrome;
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Table 2. Risk factors associated with lupus nephritis in northwestern Colombian patients (multivariate analysis).
Nephritis Without nephritis OR 95% CI p
n=39 (%) n=100 (%)
Malar erythema 77 45 4.4   1.8 - 10.8 0.001
Oral ulcers 41 21 3.1 1.3 - 7.5 0.01
Hypertension 60 10 13.7  5 - 37 0.00001
Hyperlipidemia 30 7 8.1 2.5 - 27 0.0006
proteinuria was present in 36 patients (92%). A
renal biopsy was performed in 25 (64%) patients,
with the corresponding reports indicating WHO
grades III and IV in 20 cases (80%).
The frequencies of anti-DNA antibodies at onset
were higher in patients who developed lupus
nephritis (83%) as compared to patients who did
not (64%), however, these differences were not
statistically significant (OR=2.57, 95%CI: 1.03-
6.41, p=0.06). The presence of ANA (97% vs.
94%), anti-Sm (37% vs 42%), anti-RNP (42% vs.
44%), anti-Ro (38% vs 47%), anti-La (32% vs.
31%), IgG anticardiolipin (44% vs. 39%), IgM
anticardiolipin  (33% vs. 34%), and lupus
anticoagulant (13% vs. 19%) at diagnosis was
similar in both groups. This autoantibody profile
Table 1. General characteristics of northwestern Colombian
patients with SLE.
Characteristic Nephritis Without
n=39 nephritis
n=100
Age, years (mean ± SD) 33 ± 14 33 ± 10
Gender, male: female 5:34 5:95
SLICC (median, IQR) 0 (0 - 5) 1 (0 - 5)
Duration of disease, 3.9 ± 4.7 3.6 ± 4.3
years (mean ± SD)
Photosensitivity* 69 61
Oral ulcers*    41** 21
Malar erythema*    77** 45
Discoid lupus* 15 10
Serositis* 20 7
Neurologic involvement* 26 21
Arthritis* 72 77
Hemolytic anemia*   3 5
Leucopenia* 47 30
Thrombocytopenia* 21 19
SD: standard deviation, IQR: interquartile ranges.
*  Clinical characteristics are reported in frequencies and
at onset of disease.
** See Table 2.
remained unchanged throughout the evolution of
the disease.
At diagnosis and over the course of SLE, patients
with nephritis as well as those without it had a
similar proportion of abnormalities in other organs.
Although the frequencies of cardiopulmonary (41%
vs. 20%) and vascular manifestations (15% vs.
6%) were higher in patients with lupus nephritis
as compared to patients without nephritis, these
differences were not statistically significant in the
multivariate analysis. Conversely, SLE patients
with nephritis had a higher prevalence of arterial
hypertension and hyperlipidemia when compared
to patients without nephritis (Table 2). Finally,
patients with nephritis required more
hospitalizations (>1) than patients without nephritis
(89% vs. 60%, OR=7.8, 95%CI: 2.1 - 29, p=0.002).
Discussion
In this study we observed that lupus nephritis
appears early during the course of SLE. Malar rash,
oral ulcers, hypertension and hyperlipidemia at
onset of disease were found to be important
associated factors. In addition, we observed that
lupus nephritis is a major risk factor leading to
repeated hospitalizations.
Although this study was not designed to evaluate
the prevalence of lupus nephritis, previous reports
from Medellín have shown that nephritis is found
frequently (up to 53%) among SLE patients (9,10).
Our results confirm previous studies showing that
lupus nephritis in northwestern Colombian patients
occurs early during the course of SLE (11,12).
Although the presence of ANA and anti-dsDNA
antibodies are useful markers for the diagnosis of
SLE, controversy exists about their value as an
indicator of disease activity or as predictor of lupus
nephritis (2,13). The relatively small numbers of
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lupus nephritis patients in this study may explain
the observed lack of association between anti-
dsDNA antibodies and nephritis. Nevertheless, its
prevalence was higher among lupus nephritis
patients than those SLE patients without renal
involvement. In a previous series of patients with
lupus nephritis from Medellín, Pinto et al. observed
that anti-Ro and anti-La antibodies were less
frequent in lupus nephritis patients than in SLE
patients without nephritis (14), suggesting a
protective role for these antibodies. It should be
emphasized that the presence of serum
autoantibodies does not, by itself, correlate with
the severity of the renal lesion. Patients with low
levels of circulating autoantibodies have been
observed to develop severe nephritis, and the
corollary is that individuals with circulating
autoantibodies have been reported to have mild
or absence of disease (2,15-17). These
observations indicate that qualitative/structural
features of antibodies, rather than the magnitude
of the immunoglobulin excess in the serum, are
important in the immunopathogenesis of lupus
nephritis.
In our study, the titers of autoantibodies were not
considered (see methods section), thus we were
unable to examine the influence of their levels on
clinical variables including lupus nephritis. Other
studies have found that patients with lupus
nephritis had significantly higher levels of anti-
dsDNA antibodies than patients with no renal
disease (18,19). Anti-dsDNA antibodies may be
present in SLE patients sera much earlier than
previously suspected. Arbuckle et al. observed
that SLE patients with a significant rise in anti-
dsDNA antibodies at diagnosis were more likely
to have renal disease than those who did not (20).
As mentioned earlier, not all antibodies can be
equally pathogenic: some cause severe nephritis
while others do not. The pathogenic, more
specifically “nephritogenic”, autoantibodies have
been characterized as being predominantly
immunoglobulin G in isotype, cationic in charge,
highly cross-reactive, and having features unique
to their antigen-binding region that predisposes
them to bind both intracellular and extracellular
antigens (21-23).
Antiphospholipid antibodies have also been
suggested to predict lupus nephritis (24). However,
others have observed a lack of association
between these antibodies and histological activity,
chronicity of lupus nephritis or proteinuria (25). In
our study, we did not find such antibodies to be
associated with lupus nephritis. Alternatively,
some studies have suggested a protective effect
of rheumatoid factor as well as anti-La/SS-B
antibodies in the development of lupus nephritis
(3,5,13,26,27).
Some clinical characteristics have been
associated with lupus nephritis, including malar
erythema, pericarditis and arterial hypertension
(5). The present study showed similar findings,
77% of the patients with lupus nephritis had malar
erythema and 60% had hypertension at diagnosis,
indicating that these manifestations are associated
with renal involvement in northwestern Colombian
patients with SLE. Previous reports have shown
that hypertension and hyperlipidaemia are also
associated with renal outcome and mortality in
patients with a long-term outcome of lupus nephritis
(24,28). Aggressive treatment of hypertension and
hyperlipidaemia is therefore essential in early lupus
nephritis in order to prevent further deterioration
of renal function as the disease progresses (29).
Although morbidity and mortality from cardio-
vascular and cerebrovascular diseases are
common among women with SLE, in a multivariate
analysis, Ward (30) found that risks for these
outcomes were not greater among women with
end-stage renal disease (ESRD) caused by lupus
nephritis than among other women without
diabetes with ESRD. Alternatively, the presence
of anti-Ro antibodies has been associated with a
greater potential for progressing to ESRD (31).
Among the Hopkins Lupus Cohort, SLE patients
with low C3 or thrombocytopenia were at greater
risk to develop later lupus nephritis (32). Petri has
highlighted that some of the predictors of later
lupus nephritis might actually represent subclinical
renal disease. For example, SLE patients who are
anemic or hypertensive are more likely to later
develop lupus nephritis (32).
As stated earlier, clinical manifestations of SLE
may vary according to ethnicity. Recently,
298
Biomédica 2003;23:293-300ANAYA J.M., URIBE M., PÉREZ A., SANCHEZ  J.F., PINTO L.F., MOLINA J.F. et al
Seligman et al. (33), in a retrospective analysis,
found that male non-European Americans
(including Mexicans and Hispanics), and patients
who were younger than 33 years at SLE diagnosis
were more likely to develop nephritis. British
studies (34) suggest that patients of Afro-
Caribbean and Asian origin living in the United
Kingdom develop a more severe disease,
including renal manifestations, than whites do.
Similarly, a French study (5) reported a higher rate
of renal complications for non-French nonwhite
patients, particularly those of West Indian and
Asian descent. In the 1980s, one of the largest
North American studies (35) found that more Asian
Americans had lupus nephritis than did European
Americans (67% vs. 22%), but failed to find
significant differences for Hispanic Americans and
African Americans. More recently, the LUMINA
study group observed that in African-American and
Hispanic (Mexican or Central American) ethnicities,
anti-dsDNA and anti-RNP antibodies were
significant predictors of the occurrence of lupus
nephritis (36).
It is well known than hospitalizations among SLE
patients is much more frequent than among the
general population (37), and that active disease
is one of the main causes of hospitalization among
those patients (38). Our study adds further
evidence indicating that lupus nephritis represents
a significantly higher risk for hospital requirements
among patients with SLE.
The design of the current study and the nature of
settings (third level hospitals) did not allow for
uniform data collection and may have affected the
classification of patients in terms of nephritis, for
example, due to differences in access to care and
resultant delays in the diagnosis of lupus or its
complications. Other limitations of our study
include the relatively small number of men. We
also lacked information that might have influenced
the risk of nephritis, including genetic and
socioeconomic factors (36,39). Longitudinal
studies are warranted to assess the prediction of
lupus nephritis on quality of life and mortality.
Finally, the current SLICC damage index was found
to be inaccurate to discriminate the severity of
SLE according to the presence of lupus nephritis
(Table 1).
In brief, we have evaluated the clinical and
immunological factors associated with lupus
nephritis in northwestern Colombian patients. We
hope that this study will serve to adopt public
health policies aimed at improving patient outcome
while simultaneously reducing disease costs. Our
study stresses the need to further investigate the
different factors associated with SLE in
Colombians before extrapolating the results
obtained to other populations (40).
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